Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002994 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 355
- Enrollment target
NCT00002994: Completed Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00002994 is a Phase 1 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 355 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (492% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002994, a Phase 1 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 355 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill solid tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Pilot study to examine the effectiveness of interleukin-2 plus monoclonal antibody in treating patients who have solid tumors.
Primary Outcome
toxicity of anti-Her2 MoAB given in combo w/ IL-2
Interventions
- BIOLOGICAL interleukin 2
- BIOLOGICAL rhuMAb
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 1997-07 |
| Est. Completion | 2002-04 |
| Phase | Phase 1 |
What the finished NCT00002994 record still lists
NCT00002994 is an interventional study that assigns participants to a tested intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (492% higher).
The record links to 0 conditions, and to 2 interventions - of which interleukin 2 is the first listed.
NCT00002994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002994 about?
NCT00002994 is a clinical study titled "Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill solid tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Pilot study to examine the effectiveness of interleukin...
What is the current status of trial NCT00002994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 355 participants. The study started on 1997-07. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00002994?
The interventions under investigation include: interleukin 2 (BIOLOGICAL), rhuMAb (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002994?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002994's enrollment target sits among peer trials
355 95th of 2000 higher than 1,906 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia